In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tranzyme Inc.

Division of Mallinckrodt PLC

Latest From Tranzyme Inc.

Bridging The Gap: Cyclenium Pharma

Emerging Company Profile: Cyclenium Pharma spoke with Scrip about macrocyclic drug discovery, which covers the molecular space between traditional small molecules and large bio-molecules, to capture the pharmacological properties of larger peptides/proteins in metabolically stable small molecules and proven in a broad range of target classes.

Infectious Diseases StartUps and SMEs

Cortendo names new chair

Cortendo, a global biopharmaceutical company focused on orphan endocrine disorders, has appointed John H Johnson chair of its board of directors and named Richard Kollender a director. These appointments, proposed by the nomination committee, were approved by shareholders during the Extraordinary General Meeting on 17 March. Mr Johnson has more than 30 years of biopharmaceutical industry experience at organizations including Johnson & Johnson, Lilly, ImClone and Pfizer. He is currently a member of the board of directors of Cempra Pharmaceuticals, Histogenics, Portola Pharmaceuticals, and Sucampo Pharmaceuticals. He previously served as chair of Dendreon and Tranzyme Pharma, and also served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ.


BioNotebook: Controversial StemCells board appointment; Portola/Daiichi Sankyo, Lexicon/JDRF, Supernus; and stock offerings

StemCells appoints former CIRM president; Daiichi Sankyo, Portola collaborate with Factor Xa inhibitor; Lexicon, JDRF partner on Phase II study; Supernus signs royalty deal; and Bluebird, Ultragenyx, Auspex and Ocera price offerings.

Metabolic Disorders Gastrointestinal

Roche in $548m macrocycle antibiotic deal

Roche has signed an antibiotic development agreement worth up to CHF500m ($548m) in up-front and milestone payments for its partner, Polyphor, another Swiss company. The deal covers the development and commercialization of privately owned Polyphor's Phase II macrocycle antibiotic, POL7080, which has potential to treat serious, drug-resistant hospital infections.

See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
  • Alias(es)
  • Tranzyme Pharma Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Mallinckrodt PLC
  • Senior Management
  • David Moore, CBO
    Franck Rousseau, MD, CMO
  • Contact Info
  • Tranzyme Inc.
    Phone: (919) 474-0020
    5001 S. Miami Blvd.
    Ste. 300
    Durham, NC 27703